Vladonix
Research OnlyA cytamin-class peptide supplement derived from thymus tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for immune support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Thymus cytamin · Thymic peptide supplement · A-6 thymus peptides
Mostly preclinical · 1 human study
- Preclinical
- 75%
- Human research
- 13%
Based on 8 cited sources
Numeric assessment unreviewed
A historical numeric score is recorded but has not passed a current, compound-specific assessment review. No numeric score is displayed.
This is a limitation of the numeric assessment, not a measured absence of benefit. It does not re-review the separately recorded catalogue classification or establish efficacy or safety.
Mechanism of Action
Vladonix is a cytamin-class supplement containing peptide complexes derived from thymus tissue.
Cytamin Classification
Cytamins are oral peptide supplements in the Russian bioregulator framework, distinct from injectable bioregulators:
- Derived from animal tissue extracts
- Contain multiple peptide fractions
- Marketed as dietary supplements
- Not single defined compounds
Proposed Mechanisms
- Thymic Support - Claimed to support T-cell maturation via peptide signaling
- Immune Modulation - Proposed effects on immune cell function
- Age-Related Decline - Marketed to address thymic involution
Important Limitations
- NOT a defined single peptide - contains complex mixture
- No Western clinical validation
- Oral bioavailability of peptides generally very low
- No randomized controlled trials
- Not approved by any Western regulatory agency
Thymalin
CompatibleBoth target thymus function - Thymalin is injectable extract, Vladonix is oral cytamin supplement. May have overlapping mechanisms.
Thymosin-Alpha-1
CompatibleBoth target immune function but different origins - Ta1 is defined 28-AA peptide with FDA orphan status, Vladonix is Russian cytamin supplement.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Use the source links in the research discussion above to inspect the referenced records.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength labels summarize the cited material for this entry and should be read alongside its population, model, and study limitations.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Vladonix
Related Peptides
Alpha-Defensins
HNP-1 · HNP-2 · HNP-3 +5
A family of small cationic antimicrobial peptides (29-35 amino acids) that are key components of innate immunity in humans. Produced primarily by neutrophils (HNP-1 to 4) and Paneth cells (HD-5, HD-6), they exhibit broad-spectrum antimicrobial activity and immunomodulatory functions. Well-characterized biochemically with extensive research, though therapeutic development faces challenges.
KPV
Lys-Pro-Val · Lysine-Proline-Valine · alpha-MSH(11-13) +1
Lys-Pro-Val is the C-terminal tripeptide motif of alpha-MSH. KPV reduced inflammatory readouts in cell and mouse colitis models, including a PepT1 uptake study. Human drug exposure, pharmacokinetics, safety and clinical benefit remain unestablished.
Kristagen
EDG · Glu-Asp-Gly · Immune tripeptide
A synthetic tripeptide (Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to regulate thymus function and support immune cell differentiation. No Western clinical validation exists; research is limited to Russian preclinical studies.
Lactoferricin
LFcinB · Lactoferricin B · LfcinB +1
An antimicrobial peptide derived from lactoferrin, a protein found in milk and other secretions. Shows broad-spectrum antimicrobial activity in laboratory studies. Research focuses on potential applications in infectious disease, food safety, and cancer. Primarily studied preclinically with very limited human clinical data. Not approved as a therapeutic by any regulatory agency.
LL-37
LL37 · Human cathelicidin antimicrobial peptide LL-37
LL-37 is the active human cathelicidin peptide. Three topical wound trials studied native LL-37, with mixed outcomes; an oral trial used engineered bacteria expressing LL-37. These results do not establish systemic benefit.
Murepavadin
POL7080 · RG7929
A first-in-class cyclic antimicrobial peptide targeting the LptD outer membrane protein of Pseudomonas aeruginosa. The first OMPTA (outer membrane protein targeting antibiotic) to reach clinical development. IV formulation discontinued due to nephrotoxicity; inhaled formulation continues Phase 3 development for cystic fibrosis and bronchiectasis patients.